Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.
Infectious diseases · J Infect Dis · 2026-11-16
RCTn = 51
Borriello et al. Randomized, Double-Blind, Placebo-Controlled First-in-Human Trial of a First-in-Class AI-Designed Monoclonal Antibody (GB-0669) Against the Conserved SARS-CoV-2 Spike S2 Stem HelixInfectious diseases · J Infect Dis · 2026-11-16
Secondary analysisn = 10,723
Skellington et al. The Effect of Prevaccination Analgesics on Influenza Vaccine Immunogenicity and EffectivenessInfectious diseases · Clin Infect Dis · 2026-10-28
Secondary analysis
Pardo-Seco et al. A Bayesian Re-analysis of the GALFLU Trial of High-Dose vs Standard-Dose Influenza Vaccine Against Hospitalization OutcomesInfectious diseases · Clin Infect Dis · 2026-10-28
RCTn = 833
Bonten et al. Immunogenicity and Safety of Coadministration of AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine and a COVID-19 mRNA Vaccine in Adult s Aged ≥50 Years: A Phase 3, Randomized, Noninferiority TrialInfectious diseases · Clin Infect Dis · 2026-10-28
Meta-analysisn = 37 studies
Liu et al. SARS-CoV-2 Vaccination and Attenuation of Breakthrough Infection Severity: A Systematic Global Review and Meta-analysisInfectious diseases · Vaccine · 2026-10-27
Secondary analysis
Mishin et al. Hemagglutinin- and neuraminidase-targeting antibody responses after receipt of egg-based inactivated or recombinant influenza vaccines among adults aged 18-64 yearsInfectious diseases · J Infect Dis · 2026-10-15
Secondary analysis
Narayan et al. Serum Virus-Neutralizing Antibody Titers in Clinical Trial Participants With and Without Immunocompromise Receiving Pemivibart, a Long-Acting Monoclonal Antibody for COVID-19Infectious diseases · Vaccine · 2026-10-13
RCTn = 4,000
Prasert et al. Safety and immunogenicity of Thailand Government Pharmaceutical Organization (GPO) produced, COVID-19 vaccine, 10 μg HXP-GPOVac: A Phase III, double-blind, randomized trial in comparison with VAXZEVRIAInfectious diseases · Clin Infect Dis · 2026-10-07
RCTn = 114
Byrne et al. Phase 2a Randomized Placebo-Controlled Human Challenge Trial of the Respiratory Syncytial Virus L-Protein Inhibitor S-337395 for Respiratory Syncytial Virus InfectionInfectious diseases · Clin Infect Dis · 2026-10-07
RCT
Cosgrove et al. A Phase 1/2 Dose-Ranging Safety and Immunogenicity Study of mRNA-Based Candidate Pandemic Influenza Vaccines in Healthy AdultsInfectious diseases · J Infect Dis · 2026-09-23
Secondary analysis
Freyn et al. Cell-Mediated Immunity of mRNA-1283 Vaccine Encoding SARS-CoV-2 Spike Receptor-Binding and N-Terminal Domains in Preclinical and Clinical StudiesInfectious diseases · Vaccine · 2026-09-17
RCTn = 110
Laoharattanahirun et al. Immunogenicity and safety of high-dose versus standard-dose quadrivalent inactivated influenza vaccine in patients living with HIV: a randomized controlled trialInfectious diseases · Lancet Microbe · 2026-09-15
Meta-analysisn = 35 studies
Stadler et al. COVID-19 vaccine effectiveness in people on immunosuppressive therapies: a systematic review and meta-analysisInfectious diseases · J Infect · 2026-09-14
RCTn = 63
Ortega-Francisco et al. Phase 2 evaluation of two GEO-CM04S1 dose levels shows comparable safety and broad immunogenicityInfectious diseases · Vaccine · 2026-09-05
RCTn = 586
C et al. The platform trial in COVID-19 priming and BOOsting (PICOBOO): The reactogenicity of nine licensed COVID-19 vaccines delivered in immunocompetent adultsInfectious diseases · Clin Infect Dis · 2026-09-02
Meta-analysisn = 1,181,254
Reimer Jensen et al. Electronic Nudges to Increase Influenza Vaccination in Immunosuppressed Adults Across the Age Spectrum: A Pooled Analysis of 2 Nationwide Randomized TrialsInfectious diseases · Clin Infect Dis · 2026-09-02
RCTn = 206
Loubet et al. Recombinant vs Standard Influenza Vaccine in Adults With Severe Obesity: A Randomized Clinical TrialInfectious diseases · Clin Infect Dis · 2026-09-02
Meta-analysisn = 12 trials
Gilmore et al. Indirect Influenza Vaccine Effectiveness Under Randomized Conditions: A Systematic Review and Meta-AnalysisInfectious diseases · Clin Infect Dis · 2026-08-24
Guideline
Shumaker et al. 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Antiviral Treatment for Mild to Moderate COVID-19 in AdultsInfectious diseases · Clin Infect Dis · 2026-08-24
Guideline
Nadig et al. 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Baricitinib vs. Tocilizumab